SCYNEXIS to Participate in Upcoming September Investor Conferences
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that Marco Taglietti, President and CEO, will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2022, from 3:30 p.m. to 4:00 p.m. EDT, and at the Ladenburg Thalmann Annual Healthcare Conference on September 29, 2022, from 12:00 p.m. to 12:25 p.m. EDT. Both presentations will include company insights and 1:1 meetings with attendees. SCYNEXIS focuses on innovative medicines to combat drug-resistant infections, with their lead product, BREXAFEMME, approved by the FDA on June 1, 2021.
- None.
- None.
JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Annual Global Investment Conference and the Ladenburg Thalmann Annual Healthcare Conference.
| Event: | H.C. Wainwright 24th Annual Global Investment Conference, New York |
| Date: | Wednesday September 14, 2022 |
| Time: | 3:30 p.m. – 4:00 p.m. EDT |
| Format: | Company presentation and 1:1 meetings |
| Registration: | Link |
| Event: | Ladenburg Thalmann 2022 Annual Healthcare Conference, New York |
| Date: | Thursday, September 29, 2022 |
| Time: | 12:00 p.m. – 12:25 p.m. EDT |
| Format: | Company presentation and 1:1 meetings |
| Webcast: | Link |
The presentations and archived webcasts can be found on the SCYNEXIS website here for 30 days following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. The FDA has accepted the Company’s sNDA submission for prevention of recurrent vulvovaginal candidiasis (VVC) and assigned a PDUFA decision date of November 30, 2022. In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.
CONTACTS:
Investors
Irina Koffler
LifeSci Advisors, LLC
646-970-4681
ikoffler@lifesciadvisors.com
Media
Debbie Etchison
SCYNEXIS
debbie.etchison@scynexis.com
FAQ
What event is SCYNEXIS presenting at on September 14, 2022?
When is SCYNEXIS's presentation at the Ladenburg Thalmann Annual Healthcare Conference?
What is BREXAFEMME and when was it approved by the FDA?
What is the focus of SCYNEXIS's research and products?
How can I access the SCYNEXIS presentation webcasts?
